| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 1233 York Avenue, 16 I, New York, New York 10021
2 Department of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, 1233 York Avenue, 16 I, New York, New York 10021
Correspondence: Address correspondence and reprint requests to: Chandrakanth Are, MD; E-mail: chandrakanth{at}hotmail.com.
Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors known to affect humans and carries a dismal prognosis. Our primary aim was to review its epidemiology, biology, risk factors, and prognostic indicators. We also reviewed the individual and combined roles of surgery, radiotherapy, chemotherapy, and newer therapeutic options in the management of ATC.
Methods: An extensive literature review was conducted to include all published reports on ATC. The changing trends in the management of anaplastic thyroid cancer were analyzed to summarize the current practice of management of ATC.
Results: Although ATC is rare, there has been a decline in its incidence worldwide. ATC accounts for more than half of the 1200 deaths per year attributed to thyroid cancer. Long-term survivors are rare, with >75% and 50% of patients harboring cervical nodal disease and metastatic disease, respectively, at presentation. ATC can arise de novo or from preexisting well-differentiated thyroid cancer. Surgical management has shifted from tracheostomy only for palliation to curative resection when possible. Tracheostomy is performed for impending obstruction rather than for prophylaxis. Radiotherapy has evolved from postoperative administration only to preoperative treatment, combining preoperative and postoperative treatment and using higher doses, along with hyperfractionating and accelerating dose schedules. Chemotherapy has changed from monotherapy to combination therapy, and newer drugs such as paclitaxel show promise. Similarly, novel angiogenesis-inhibiting agents are currently being used, with early reports of some benefit.
Conclusions: Despite multimodality approaches, ATC still carries a dismal prognosis. This should provoke innovative strategies beyond conventional methods to tackle this uniformly lethal disease.
Key Words: Anaplastic thyroid carcinoma • Biology • Pathogenesis • Prognostic factors • Treatment approaches
This article has been cited by other articles:
 |
|
 |
|
  Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.-G. Delcros, M. Toller, F. Curcio, F. S Ambesi-Impiombato, M. D'Armiento, and S. Ulisse Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines Endocr. Relat. Cancer, June 1, 2008; 15(2): 559 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Radiology Quiz Case 1: Diagnosis Arch Otolaryngol Head Neck Surg, April 1, 2008; 134(4): 444 - 444. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Klopper, A. Berenz, W. R. Hays, V. Sharma, U. Pugazhenthi, J. Janssen, M. Singh, R. P. Bissonnette, and B. R. Haugen In vivo and Microarray Analysis of Rexinoid-Responsive Anaplastic Thyroid Carcinoma Clin. Cancer Res., January 15, 2008; 14(2): 589 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. De Falco, V. Guarino, E. Avilla, M. D. Castellone, P. Salerno, G. Salvatore, P. Faviana, F. Basolo, M. Santoro, and R. M. Melillo Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer Cancer Res., December 15, 2007; 67(24): 11821 - 11829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Are, J. F. Hsu, R. A. Ghossein, H. Schoder, J. P. Shah, and A. R. Shaha Histological Aggressiveness of Fluorodeoxyglucose Positron-Emission Tomogram (FDG-PET)-Detected Incidental Thyroid Carcinomas Ann. Surg. Oncol., November 1, 2007; 14(11): 3210 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Lopez, J. Wang-Rodriguez, C. Chang, J. S. Chen, F. S. Pardo, J. Aguilera, and W. M. Ongkeko Gefitinib Inhibition of Drug Resistance to Doxorubicin by Inactivating ABCG2 in Thyroid Cancer Cell Lines Arch Otolaryngol Head Neck Surg, October 1, 2007; 133(10): 1022 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Henderson, M. J. Fredrick, and G. L. Clayman Differential Responses of Human Papillary Thyroid Cancer Cell Lines Carrying the RET/PTC1 Rearrangement or a BRAF Mutation to MEK1/2 Inhibitors Arch Otolaryngol Head Neck Surg, August 1, 2007; 133(8): 810 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Wiseman, O. L. Griffith, S. Deen, A. Rajput, H. Masoudi, B. Gilks, L. Goldstein, A. Gown, and S. J. M. Jones Identification of Molecular Markers Altered During Transformation of Differentiated Into Anaplastic Thyroid Carcinoma Arch Surg, August 1, 2007; 142(8): 717 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gomez-Rivera, A. A. Santillan-Gomez, M. N. Younes, S. Kim, D. Fooshee, M. Zhao, S. A. Jasser, and J. N. Myers The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model Clin. Cancer Res., August 1, 2007; 13(15): 4519 - 4527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Conticello, L. Adamo, R. Giuffrida, L. Vicari, A. Zeuner, A. Eramo, G. Anastasi, L. Memeo, D. Giuffrida, G. Iannolo, et al. Proteasome Inhibitors Synergize with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Anaplastic Thyroid Carcinoma Cell Death J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1938 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Stoler, N. J. Nowak, S.-i. Matsui, S. M. Wiseman, N. Chen, S. S. Dutt, J. D. Bartos, T. R. Loree, N. R. Rigual, W. L. Hicks Jr, et al. Comparative Genomic Instabilities of Thyroid and Colon Cancers Arch Otolaryngol Head Neck Surg, May 1, 2007; 133(5): 457 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Brignardello, M. Gallo, I. Baldi, N. Palestini, A. Piovesan, E. Grossi, G. Ciccone, and G. Boccuzzi Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years Eur. J. Endocrinol., April 1, 2007; 156(4): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nahari, R. Satchi-Fainaro, M. Chen, I. Mitchell, L. B. Task, Z. Liu, J. Kihneman, A. B. Carroll, L. S. Terada, and F. E. Nwariaku Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer Mol. Cancer Ther., April 1, 2007; 6(4): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Jones, R Spendiff, S Fareedi, and P S Richards The role of ultrasound in the management of nodular thyroid disease Imaging, March 1, 2007; 19(1): 28 - 38. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
